Sarcoma News

Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General Practitioner’s Oral Contraception Study.

CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology.

The FDA denied approval of Coherus BioSciences’ biologics license application for CHS-1701, a proposed biosimilar for pegfilgrastim.

President Donald J. Trump selected Norman E. “Ned” Sharpless, MD, to serve as director of NCI.

Foundation Medicine, NCI and ECOG-ACRIN Cancer Research Group entered a collaboration to evaluate the benefit of genomically guided treatments targeting specific alterations within a patient’s tumor, regardless of cancer type.

Last week was a first for me — I participated in a Facebook live event.

CHICAGO — Routine genomic testing of tumor samples appears feasible and enabled more personalized treatment, according to the results of the ProfiLER study conducted in France and presented at the ASCO Annual Meeting.

CHICAGO — Efforts to modify treatments in an attempt to preserve high cure rates while reducing potential late effects have translated to improved health outcomes for childhood cancer survivors, Todd M. Gibson, PhD, assistant member at St. Jude Children’s Research Hospital, said at the ASCO Annual Meeting.

CHICAGO — ASCO’s big-data initiative CancerLinQ announced a long-term partnership with the FDA to use patient data to evaluate the real-world use of newly approved cancer therapies, according to a press release.

CHICAGO — Larotrectinib — the first selective small-molecule pan-tropomyosin receptor kinase inhibitor — demonstrated clinical activity in adults and children with various tumors that had neurotrophic tyrosine receptor kinase gene fusions, according to study results presented at the ASCO Annual Meeting.